Document is current

Article History

Received: 15 April 2018

Accepted: 26 September 2018

First Online: 4 October 2018

Ethics approval and consent to participate

: Informed written consent was obtained for each enrolled patient in the trial. The FIGHTDIGO study was approved by the ethics committee (Committee for the Protection of Person EST I DIJON, 25 March 2016) and was registered in ExternalRef removed (NCT02797197).

: none

: Damien Botsen reports personal fees from Pierre Fabre and non-financial support from GlaxoSmithKline, Novartis, Chugai, and Amgen outside the submitted work.Camille Mazza reports personal fees from Pierre Fabre outside the submitted work.Mathilde Brasseur reports personal fees from Bayer and non-financial support from Pierre Fabre, Novartis, Amgen, Roche, and AbbVie outside the submitted work.Olivier Bouche reports grants from Roche, personal fees from Roche, grants from Pierre Fabre, personal fees from Pierre Fabre, personal fees from Amgen, personal fees from Bayer, personal fees from Lilly, personal fees from Merck, personal fees from Novartis, outside the submitted work.Yohann Renard reports grants from Bard and Allergan, outside the submitted work. Marie-Amélie Ordan, Marine Perrier, Johanna Moreau, Coralie Barbe, Florian Slimano, Barbara Taillière, Eric Bertin: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.